Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ferozsons LaboratoriesKAR:FEROZ +3.41%68 5-Year Yield-on-Cost % is 1.09 as of Sep. 05, 2026, which is 51% below its 10-year median of 2.24. GuruFocus rates KAR:FEROZ with a GF Score™ of 68/100 and a GF Value™ of ₨431.87 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 508 Drug Manufacturers companies, Ferozsons Laboratories ranks worse than 70.28% on this metric.
Ferozsons Laboratories's yield on cost for the quarter that ended in Mar. 2026 was 1.09.
The historical rank and industry rank for Ferozsons Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:
KAR:FEROZ'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.7 Med: 2.24 Max: 5.51
Current: 1.09
During the past 11 years, Ferozsons Laboratories's highest Yield on Cost was 5.51. The lowest was 0.70. And the median was 2.24.
KAR:FEROZ's 5-Year Yield-on-Cost % is ranked worse than 70.28% of 508
companies
in the Drug Manufacturers industry
Industry Median: 2.305
vs KAR:FEROZ: 1.09
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Ferozsons Laboratories 5-Year Yield-on-Cost % Related Terms
KAR:FEROZ vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ferozsons Laboratories 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Ferozsons Laboratories's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Ferozsons Laboratories (KAR:FEROZ) has a 5-Year Yield-on-Cost % of 1.09 as of Sep. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ferozsons Laboratories and its competitors. This is 51% below median its historical median of 2.24. Over the past decade, Ferozsons Laboratories' 5-Year Yield-on-Cost % has ranged from 0.70 to 5.51. According to the industry distribution chart, Ferozsons Laboratories ranks #357 out of 508 companies in the Drug Manufacturers industry, placing it in the top 70.3%.
Is Ferozsons Laboratories' 5-Year Yield-on-Cost % too high?
Ferozsons Laboratories' current 5-Year Yield-on-Cost % of 1.09 is 51% below median its 10-year median of 2.24. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 5.51. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.31. Ferozsons Laboratories' value of 1.09 is 52.7% below this industry median. Based on the distribution chart, Ferozsons Laboratories ranks #357 out of 508 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ferozsons Laboratories has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ferozsons Laboratories ranks #357 out of 508 companies for 5-Year Yield-on-Cost %. This places Ferozsons Laboratories in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.31. Ferozsons Laboratories' value of 1.09 is 52.7% below this benchmark. Historically, Ferozsons Laboratories' own 5-Year Yield-on-Cost % has ranged from 0.70 to 5.51 over the past decade. While the company's 10-year median is 2.24 vs. the industry median of 2.31, Ferozsons Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.31, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ferozsons Laboratories's current 5-Year Yield-on-Cost % of 1.09 is 52.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ferozsons Laboratories and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ferozsons Laboratories's current 5-Year Yield-on-Cost % is 1.09, which is 51% below median its own 10-year median of 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Modestly Undervalued. The stock's GF Value™ is ₨431.87, compared to a current price of ₨367.47 — trading 14.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.09, which is 51% below median its 10-year median of 2.24 and 52.7% below the Drug Manufacturers industry median of 2.31. Ferozsons Laboratories' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current 5-Year Yield-on-Cost % is 1.09 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued.
The current stock price of ₨367.47 is trading 14.9% below its estimated GF Value™ of ₨431.87.
GuruFocus considers Ferozsons Laboratories to be Modestly Undervalued.
Key valuation signals for KAR:FEROZ:
5-Year Yield-on-Cost %: 1.09 (51% below median its 10-year median of 2.24)
GF Value™: ₨431.87 vs. price of ₨367.47 (14.9% below fair value)
Industry Position: 52.7% below the Drug Manufacturers median (#357 of 508)
No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
68GF Score
Get the complete analysis for KAR:FEROZ
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:FEROZ has been successfully added to your 
